Итраконазол

It is a triazole antifungal used in the treatment of oropharyngeal and vulvovaginal candidiasis, pityriasis versicolor, other dermatophytosis, onychomycosis and systemic fungal infections and some protozoal infections, such as Acanthamoeba keratitis, leishmaniasis and trypanosomiasis. Oral administration.

Its pharmacokinetic data (moderately high molecular weight and high percentage of protein binding) explain the no or minimal passage into milk observed ^{(McNamara 2004)}, such that a breastfed infant would receive a maximum of 35 micrograms of itraconazole daily, hundreds of times less than the paediatric dose of 5 mg/kg/day. ^{(Briggs 2015, Janssen 2014, Cazzaniga 1996)}

In addition, its low oral bioavailability and the alkaline environment of milk hinder its absorption.

It is used for the treatment of fungal infections in children, including premature infants, with good tolerance. ^{(Mahamaytakit 2014, Gupta 2013 and 2003, Dhondt 1992, Bhandari 1992)}

Itraconazole significantly increases plasma concentrations of domperidone, which has to be taken into account in case of simultaneous administration of both drugs. ^{(Yoshizato 2012)}